You are here: Industry Insights > HSIL

News List

Asieris Announces First Patient Treated in Europe in APRICITY, the Multinational Phase III Clinical Trial of APL-1702, Cevira® prnasia
June 22, 2021
Asieris Pharmaceuticals (Asieris) today announced dosing of the first patient in Europe in its multinational, multicenter, Phase III clinical trial (APRICITY) of its photodynamic drug-device combination product APL-1702, Cevira® which is being ...
INOVIO Announces Positive Results from REVEAL 1, a Phase 3 Pivotal Trial Evaluating VGX-3100, its DNA-based HPV Immunotherapy for the Treatment of High-grade Precancerous Cervical Dysplasia Caused by prnasia
March 02, 2021
INOVIO today announced it met primary and secondary endpoints among all evaluable subjects for the REVEAL 1 trial.
Cervical dysplasia treatment device approved for global Phase III trial europeanpharmaceuticalreview
July 10, 2020
The cervical dysplasia drug-device product, APL-1702 (Cevira®), offers an alternative to surgery and has been approved to start a clinical trial in China and several other countries.
Asieris Received China NMPA's Approval to Start a Global Phase III Clinical Trial for APL-1702 to Treat Cervical Precancerous Lesions (HSIL) prnasia
July 08, 2020
In addition to China, Asieris has concurrently initiated this global multi-centered Phase III clinical trial in the United States, Germany, Romania, Hungary, Russia, and Ukraine.